Valeant Peer Concordia Top Canada Stock as CEO Eyes More Deals

Concordia Healthcare Corp. is eyeing bigger targets and more assets in Europe, extending an acquisition streak that has helped make the Canadian company the top performer on the Toronto Stock Exchange this year.

Concordia has surged almost fivefold in the past 12 months as consolidation sweeps through the pharmaceutical industry. The Toronto-based company agreed to buy assets of Covis Pharma Holdings Sarl for $1.2 billion last month and will likely announce another purchase in the third quarter, Chief Executive Officer Mark Thompson said.